within Pharmacolibrary.Drugs.ATC.R;

model R03DA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 2.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diprophylline is a xanthine derivative used as a bronchodilator for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is less potent than theophylline but offers a more favorable safety profile. Diprophylline has been used in clinical practice in several countries, but its use has diminished due to the introduction of more effective and safer bronchodilators. It is not widely approved or commonly used in modern practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an adult healthy individual after a single oral administration. No specific publication with reference PK parameters was found.</p><h4>References</h4><ol><li><p>Kolbina, M, et al., &amp; Körber, M (2017). Saturated phosphatidylcholine as matrix former for oral extended release dosage forms. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 108 86–92. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2017.07.017&quot;>10.1016/j.ejps.2017.07.017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28716757/&quot;>https://pubmed.ncbi.nlm.nih.gov/28716757</a></p></li><li><p>Stablein, JJ, et al., &amp; Lockey, RF (1983). Pharmacokinetics and bioavailability of three dyphylline preparations. <i>European journal of clinical pharmacology</i> 25(2) 281–283. DOI:<a href=&quot;https://doi.org/10.1007/BF00543805&quot;>10.1007/BF00543805</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6628514/&quot;>https://pubmed.ncbi.nlm.nih.gov/6628514</a></p></li><li><p>Huang, HP, &amp; Ayres, JW (1988). Dyphylline prodrugs: plasma hydrolysis and dyphylline release in rabbits. <i>Journal of pharmaceutical sciences</i> 77(2) 104–109. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600770203&quot;>10.1002/jps.2600770203</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3361424/&quot;>https://pubmed.ncbi.nlm.nih.gov/3361424</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DA01;
